Novo’s latest investment comes just days after the U.S. FTC greenlit the highly contentious acquisition of Catalent, which analysts expect will help the pharma expand its production capacity.

Construction has already begun on the Ozempic-producer’s new Danish production facility and 40,000m² warehouse.

Danish health authorities said on Monday they would ask the European Union's drug regulator to review the findings of two Danish studies linking Novo Nordisk's popular diabetes drug Ozempic to a rare sight-threatening eye condition.